Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral Agent.
Mol Pharm
; 20(12): 6213-6225, 2023 Dec 04.
Article
in En
| MEDLINE
| ID: mdl-37917742
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
HIV-1
/
Anti-HIV Agents
Limits:
Animals
/
Humans
Language:
En
Journal:
Mol Pharm
Year:
2023
Document type:
Article